To address the growing use of ad blockers we now use affiliate links to sites like Amazon.com, streaming services, and others. Affiliate links help sites like QualityCounts.com stay open. Affiliate links cost you nothing but help me support my family. We do not allow paid reviews on this site. As an Amazon Associate I earn from qualifying purchases.  Also, you can donate  to ben@qualitycounts.com via Zelle or PayPal.  Click here for the PayPal QR.  Click here for Bitcoin QR code or Bitcoin address: 39muDw6WpQV8j6EdA8eUBvT5iFDiVpVpiE
Home ReliableRXPharmacy Past Newsletters Amazon.com Contact
 Sign-up for newsletter 
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:

Home > Health Conditions > Brain Cancer.

Brain Cancer

Related Topics:

Alternative News:

  • L-arginine Enhances Effect of Radiation on Brain Metastases - Medscape, 11/17/21 - "63 patients with brain metastases related to solid tumors — such as non-small cell lung cancer (51%), triple-negative breast cancer (21%), and melanoma (8%) — were randomized to receive oral L-arginine 10 g or placebo prior to each fraction of radiation. The whole-brain radiation therapy protocol consisted of a total dose of 32.0 Gy, administered in 20 fractions, followed by a boost of 22.4 Gy that adhered to the same fractionation schedule. The investigators used the Fisher's exact test or the Cox-Mantel test to compare responses ... The majority of patients had an uncontrolled primary tumor, multiple metastatic sites, and multiple brain metastases. The median follow-up after the end of the treatment was 5 months (range, 1 - 55 months) ... L-arginine was well tolerated and did not produce short- or long-term (more than 6 months) adverse events. The overall response rate was significantly higher in the L-arginine group than in the placebo group (77.4% vs 22.0%; P < .001), as was the symptomatic response rate (93.5% vs 50.0%; P = .002) ... Complete neurologic responses were three times more likely in patients pretreated with L-arginine than in those pretreated with placebo, although the difference was not significant (29.0% vs 9.4%; P = .059). And at 6 months, patients in the L-arginine group were four times more likely to be free from neurologic progression than patients in the placebo group (82.0% vs 20.0%; ... Median overall progression-free survival was longer in the L-arginine group than in the placebo group (5 vs 2 months" - See L-arginine products at Amazon.com.
  • Arginine, an inexpensive oral drug, could enhance radiation therapy for cancer - Science  Daily, 11/6/21 - "Arginine, also called L-arginine, is inexpensive and widely available, generally considered safe, and can get relatively easily from the bloodstream into the brain. The idea of using it to treat cancer arose from observations that tumors often aid their own survival by producing high levels of the related molecule nitric oxide (NO). The latter regulates multiple processes in the body including the flow of blood through blood vessels, and tumors cells often make more NO by upregulating their production of special enzymes called NO synthases, which synthesize NO from arginine ... patients were treated with high-dose arginine or placebo oral suspensions an hour before radiotherapy for their brain metastases -- tumors in the brain that represent the spread from primary tumors elsewhere, such as the lungs ... Six months after their courses of radiotherapy, 82 percent of the arginine group had improvement, or at least no worsening, of their neurological symptoms, compared with 20 percent in the placebo group. Most of the arginine-treated patients who died during the study did so because of their cancers' spread elsewhere in the body ... Moreover, although metastatic cancer usually has a dire prognosis, there were some arginine-treated patients whose tumors in and outside the brain disappeared, suggesting the possibility of cures" - See L-arginine products at Amazon.com.
  • Common Diabetes Drug Shrinks Brain Tumors in Mice - Medscape, 11/3/21 - "Preliminary testing in mice suggests that the diabetes drug metformin might target these tumors specifically. The drug acts on cell processes that drive the growth of posterior fossa group A (PFA) ependymomas" - See metformin at ReliableRX.
  • Supplementation with selenium-enriched yeast attenuates brain metastatic growth - Nutr Cancer. 2013;65(4):563-70 - "Mice were fed experimental diets enriched (1 mg/kg) with sodium selenite (Se-S), seleno-1-methionine (Se-Meth), a yeast-derived organic form of selenium (Se-Yeast), or a control diet (Se < 0.05 mg/kg) for 20 wk ... Mice bearing brain metastatic tumors and fed Se-Yeast- or Se-S-enriched diets displayed a higher survival rate compared with other experimental and control groups. Importantly, Se-Yeast supplementation decreased the growth of brain metastatic tumors as determined by the measurement of the intensity of the bioluminescent signal emitted by K1735-Luc cells upon reaction with luciferin. Different chemical forms of Se have distinct effects on the development of brain metastases. Organic Se in the form of Se-Yeast may be a valuable agent in suppression of brain metastatic disease" - See se-methyl l-selenocysteine at Amazon.com.

News & Research: